33 Plasma Proteomic Profiling Reveals SEZ6L2 as a Novel Biomarker in Translocation Renal Cell Carcinoma

Shane Killarney, Prathyusha Konda, Shanivi Srikonda, Michelle Hirsch, Bradley McGregor, Wenxin Xu, Toni Choueiri, Srinivas Viswanathan · 2026

Read 33 Plasma Proteomic Profiling Reveals SEZ6L2 as a Novel Biomarker in Translocation Renal Cell Carcinoma by Shane Killarney, Prathyusha Konda, Shanivi Srikonda, Michelle Hirsch, Bradley McGregor, Wenxin Xu, Toni Choueiri, Srinivas Viswanathan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13535492.txt.

Description

Shane Killarney and co-authors report a blood test study on a rare kidney cancer in 2026. The cancer, called tRCC, is set off by a gene fusion and can be harsh in both adults and children. The team used a lab assay to measure more than a thousand proteins in blood from 18 people with tRCC and 68 with other kidney cancers.

One protein, SEZ6L2, stood out as much higher in the tRCC group. High levels tied to cell growth signals and to shorter life in that group. If later work backs it up, a simple blood measure could help spot this rare cancer and flag who needs closer care.

Catalog record

CREATORShane Killarney, Prathyusha Konda, Shanivi Srikonda, Michelle Hirsch, Bradley McGregor, Wenxin Xu, Toni Choueiri, Srinivas Viswanathan
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE1 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13535492

Browse the full library · About the Tower of Babel